158 related articles for article (PubMed ID: 24059600)
41. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
Hou MM; Wang Z; Janku F; Piha-Paul S; Naing A; Hong D; Westin S; Coleman RL; Sood AK; Tsimberidou AM; Subbiah V; Wheler J; Zinner R; Lu K; Meric-Bernstam F; Fu S
Oncotarget; 2016 Jun; 7(23):35132-43. PubMed ID: 27147567
[TBL] [Abstract][Full Text] [Related]
42. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.
Landrum LM; Java J; Mathews CA; Lanneau GS; Copeland LJ; Armstrong DK; Walker JL
Gynecol Oncol; 2013 Jul; 130(1):12-8. PubMed ID: 23578540
[TBL] [Abstract][Full Text] [Related]
43. High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer.
Liu M; Mor G; Cheng H; Xiang X; Hui P; Rutherford T; Yin G; Rimm DL; Holmberg J; Alvero A; Silasi DA
Reprod Sci; 2013 May; 20(5):605-15. PubMed ID: 23171677
[TBL] [Abstract][Full Text] [Related]
44. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
45. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
[TBL] [Abstract][Full Text] [Related]
46. Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence.
Champer M; Huang Y; Hou JY; Tergas AI; Burke WM; Hillyer GC; Ananth CV; Neugut AI; Hershman DL; Wright JD
Gynecol Oncol; 2018 Jan; 148(1):19-27. PubMed ID: 29153542
[TBL] [Abstract][Full Text] [Related]
47. Splenectomy as Part of Cytoreductive Surgery in Recurrent Epithelial Ovarian Cancer.
Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
Anticancer Res; 2015 Sep; 35(9):5097-101. PubMed ID: 26254413
[TBL] [Abstract][Full Text] [Related]
48. Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer.
Hızlı D; Boran N; Yılmaz S; Turan T; Altınbaş SK; Celik B; Köse MF
Eur J Obstet Gynecol Reprod Biol; 2012 Jul; 163(1):71-5. PubMed ID: 22480413
[TBL] [Abstract][Full Text] [Related]
49. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Oza A; Kaye S; Van Tornout J; Sessa C; Gore M; Naumann RW; Hirte H; Colombo N; Chen J; Gorla S; Poondru S; Singh M; Steinberg J; Yuen G; Banerjee S
Gynecol Oncol; 2018 May; 149(2):275-282. PubMed ID: 29454514
[TBL] [Abstract][Full Text] [Related]
50. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
[TBL] [Abstract][Full Text] [Related]
51. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
52. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
[TBL] [Abstract][Full Text] [Related]
53. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S
Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
[TBL] [Abstract][Full Text] [Related]
54. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
55. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
[TBL] [Abstract][Full Text] [Related]
56. Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data.
Manci N; Bellati F; Muzii L; Calcagno M; Alon SA; Pernice M; Angioli R; Panici PB
Ann Surg Oncol; 2006 Dec; 13(12):1717-23. PubMed ID: 16957965
[TBL] [Abstract][Full Text] [Related]
57. Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study.
Petrillo M; Amadio G; Salutari V; Paris I; Di Stefano MG; Ferandina G; Scambia G; Fagotti A
Gynecol Oncol; 2016 Aug; 142(2):231-6. PubMed ID: 27215633
[TBL] [Abstract][Full Text] [Related]
58. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH
Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410
[TBL] [Abstract][Full Text] [Related]
59. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
60. Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients.
Zang RY; Yang WT; Shi DR; Xing Y; Cai SM
J Surg Oncol; 2005 Jul; 91(1):67-72. PubMed ID: 15999350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
